Showing results (731-740 of 768) with videos related to

Sort By:
Pageof 77
The Journal of Clinical Investigation|April 9, 2013
HIF1α and HIF2α independently activate SRC to promote melanoma metastasesSara C Hanna, Bhavani Krishnan, Sean T Bailey, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 2022
Pembrolizumab Versus Placebo as Second-Line Therapy in Patients From Asia With Advanced Hepatocellular Carcinoma: A Randomized, Double-Blind, Phase III TrialShukui Qin, Zhendong Chen, Weijia Fang, et al.
Plos Medicine|December 7, 2016
Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple MetastasesKatherine A Hoadley, Marni B Siegel, Krishna L Kanchi, et al.
The Journal of Biological Chemistry|July 20, 2011
Improvement of a potential anthrax therapeutic by computational protein designSean J Wu, Christopher B Eiben, John H Carra, et al.
Plos Medicine|January 10, 2017
Correction: Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple MetastasesKatherine A Hoadley, Marni B Siegel, Krishna L Kanchi, et al.
Annals of Hepatology|December 26, 2025
Effect of pembrolizumab on viral hepatitis load and transaminases in advanced hepatocellular carcinomaStephen Lam Chan, Richard S Finn, Julien Edeline, et al.
Cancer Research Communications|February 27, 2026
Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 StudyStephen L Chan, Thomas Yau, Robin K Kelley, et al.
Transplantation|August 7, 2012
Diabetes, body mass index, and outcomes in hepatocellular carcinoma patients undergoing liver transplantationAbby B Siegel, Emerson A Lim, Shuang Wang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 2, 2026
Pembrolizumab Monotherapy in Sorafenib-Treated and Treatment-Naive Advanced Hepatocellular Carcinoma: Long-Term Follow-Up of Open-Label, Phase 2 KEYNOTE-224 StudyRichard S Finn, Masatoshi Kudo, Ivan Borbath, et al.
Neuro-Oncology|May 10, 2017
Combined kinase inhibitors of MEK1/2 and either PI3K or PDGFR are efficacious in intracranial triple-negative breast cancerAmanda E D Van Swearingen, Maria J Sambade, Marni B Siegel, et al.
Pageof 77